tbuckley/cabot-search huggingface dataset:
Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors
Authors: Hao Li, Shuai Wang, Zhengqiang Yang, Xianwei Meng, Meng Niu
Journal: Bioactive Materials (2024)

The treatment of digestive system tumors presents challenges, particularly in immunotherapy, owing to the advanced immune tolerance of the digestive system. Nanomaterials have emerged as a promising approach for addressing these challenges. They provide targeted drug delivery, enhanced permeability, high bioavailability, and low toxicity. Additionally, nanomaterials target immunosuppressive cells and reshape the tumor immune microenvironment (TIME). Among the various cells in the TIME, tumor-associated macrophages (TAMs) are the most abundant and play a crucial role in tumor progression. Therefore, investigating the modulation of TAMs by nanomaterials for the treatment of digestive system tumors is of great significance. Here, we present a comprehensive review of the utilization of nanomaterials to modulate TAMs for the treatment of gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer. We also investigated the underlying mechanisms by which nanomaterials modulate TAMs to treat tumors in the digestive system. Furthermore, this review summarizes the role of macrophage-derived nanomaterials in the treatment of digestive system tumors. Overall, this research offers valuable insights into the development of nanomaterials tailored for the treatment of digestive system tumors.
Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation
Authors: Errol Moras, Kruti Gandhi, Anoop N. Koshy, Kirtipal Bhatia, Chayakrit Krittanawong, Abel Casso Dominguez, Edgar Argulian, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2024)
Cancer control collaborations between China and African countries
Authors: Twalib Ngoma, Isaac Adewole, Victoria Ainsworth, David Chin, Jennifer Chin, Ahmed Elzawawy, Adedayo Joseph, Abba Mallum, Ntokozo Ndlovu, Mamsau Ngoma, Aishat Oladipo, William Swanson, Wilfred Ngwa
Journal: The Lancet Oncology (2024)
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions
Authors: Michael Schlander, Wim van Harten, Valesca P Retèl, Phu Duy Pham, Julie M Vancoppenolle, Jasper Ubels, Olaya Seoane López, Camila Quirland, Felipe Maza, Eline Aas, Bernd Crusius, Agustín Escobedo, Nora Franzen, Jeanette Fuentes-Cid, Diego Hernandez, Karla Hernandez-Villafuerte, Iva Kirac, Artus Paty, Thierry Philip, Sigbjørn Smeland, Richard Sullivan, Elena Vanni, Sinisa Varga, Thomas Vermeulin, Rachel D Eckford
Journal: The Lancet Oncology (2024)
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
Authors: Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E Yin, Allison L Agwu, Conn Harrington, Rodica M Van Solingen-Ristea, Cynthia C McCoig, Adeola Adeyeye, Jared Kneebone, Vasiliki Chounta, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Jessica D'Angelo, Allison Bearden, Herta Crauwels, Jenny Huang, Sarah Buisson, Ryan Milligan, Shawn Ward, Carolyn Bolton-Moore, Aditya H Gaur, Brookie M Best, Edmund V Capparelli, Sherika Hanley, Sisinyana Ruth Mathiba, Megeshinee Naidoo, Pradthana Ounchanum, Faeezah Patel, Mary E Paul, Ellen Townley, Kati Vandermeulen, Kyle Whitson, Sara Zabih
Journal: The Lancet HIV (2024)
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Authors: Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, E Claire Dees, Peter Kabos, Samuel Suzuki, Sarah C Mutka, Brian F Sullivan, Igor Gorbatchevsky, Robert Wesolowski
Journal: The Lancet Oncology (2024)
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease
Authors: Matthieu Wargny, Christophe Leux, Gilles Chatellier, Sandrine Coudol, Pierre-Antoine Gourraud, Yann Gouëffic
Journal: Journal of the American College of Cardiology (2024)
Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients With Cyanotic Congenital Heart Disease
Authors: Fu-Tsuen Lee, Liqun Sun, Joshua F.P. van Amerom, Sharon Portnoy, Davide Marini, Amandeep Saini, Natasha Milligan, Jessie Mei Lim, Brahmdeep Saini, Thiviya Selvanathan, Vanna Kazazian, Renee Sananes, Edgar Jaeggi, John C. Kingdom, Christopher K. Macgowan, Linh Ly, Vann Chau, Steven P. Miller, Mike Seed
Journal: Journal of the American College of Cardiology (2024)

Fetuses with cyanotic congenital heart disease (CHD) exhibit profound fetal circulatory disturbances that may affect early outcomes. This study sought to investigate the relationship between fetal hemodynamics and early survival and neurodevelopmental (ND) outcomes in patients with cyanotic CHD. In this longitudinal observational study, fetuses with cyanotic CHD underwent late gestational fetal cardiovascular magnetic resonance (CMR) to measure vessel blood flow and oxygen content. Superior vena cava (SVC) flow was used as a proxy for cerebral blood flow. Primary outcomes were 18-month mortality and Bayley Scales of Infant Development-III assessment. A total of 144 fetuses with cyanotic CHD were assessed. By 18 months, 18 patients (12.5%) died. Early mortality was associated with reduced combined ventricular output (P = 0.01), descending aortic flow (P = 0.04), and umbilical vein flow (P = 0.03). Of the surviving patients, 71 had ND outcomes assessed. Cerebral oxygen delivery was the fetal hemodynamic variable most strongly associated with cognitive, language, and motor outcomes (P < 0.05). Fetal SVC flow was also associated with cognitive, language, and motor outcomes (P < 0.01), and it remained an independent predictor of cognitive (P = 0.002) and language (P = 0.04) outcomes after adjusting for diagnosis. Diminished SVC flow also performed better than other fetal CMR and echocardiographic predictors of cognitive ND delay (receiver-operating characteristic curve area: 0.85; SE 0.05). Among fetuses with cyanotic CHD, diminished fetal combined ventricular output is associated with mortality, whereas cerebral blood flow and oxygen delivery are associated with early cognitive, language, and motor development at 18 months of age. These results support the inclusion of fetal CMR to help identify patients at risk of adverse ND outcomes.
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Authors: Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Ann M Leen, Mengfen Wu, Linda C Sandin, Jessica Wenthe, Emma Eriksson, Gustav J Ullenhag, Bambi Grilley, Justyna Leja-Jarblad, Susan G Hilsenbeck, Malcolm K Brenner, Angelica S I Loskog
Journal: The Lancet Oncology (2024)
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
Authors: Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, Ludovic Evesque, Denis Smith, Nicolas Badet, Emmanuelle Samalin, Daniel Lopez-Trabada Ataz, Aurelie Parzy, Jérôme Desramé, Nabil Baba Hamed, Bruno Buecher, David Tougeron, Olivier Bouché, Laetitia Dahan, Benoist Chibaudel, Farid El Hajbi, Laurent Mineur, Olivier Dubreuil, Meher Ben Abdelghani, Solange Pecout, Frederic Bibeau, Michael Herfs, Marie-Line Garcia, Aurelia Meurisse, Dewi Vernerey, Julien Taïeb, Christophe Borg
Journal: The Lancet Oncology (2024)
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
Authors: Robert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, Serigne N Lo, Robyn P M Saw, Alexander H R Varey, Richard A Scolyer, Georgina V Long, John F Thompson, Piotr Rutkowski, Ulrich Keilholz, Alexander C J van Akkooi, Cornelis Verhoef, David van Klaveren, Dirk J Grünhagen
Journal: The Lancet Oncology (2024)
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Authors: Egbert F Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz-Ares Rodríguez, Jose M Pacheco, Bob T Li, David Planchard, Christina Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A Jänne
Journal: The Lancet Oncology (2024)
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Authors: Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, John H Moye, Barbara Heckman, Elizabeth D Lowenthal, Shawn Ward, Ryan Milligan, Pearl Samson, Brookie M Best, Conn M Harrington, Susan L Ford, Jenny Huang, Herta Crauwels, Kati Vandermeulen, Allison L Agwu, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Pradthana Ounchanum, Jared L Kneebone, Ellen Townley, Carolyn Bolton Moore, Sarah Buisson, S. Y. Amy Cheung, Vasiliki Chounta, Isabelle Deprez, Alicia Catherine Desmond, Kelong Han, Sherika Hanley, Yu-Wei Lin, Faeezah Patel, Mary E. Paul, Gilly Roberts, Kyle Whitson, Sara Zabih
Journal: The Lancet HIV (2024)
Engineering customized nanovaccines for enhanced cancer immunotherapy
Authors: Jinyu Guo, Changhua Liu, Zhaoyang Qi, Ting Qiu, Jin Zhang, Huanghao Yang
Journal: Bioactive Materials (2024)

Nanovaccines have gathered significant attention for their potential to elicit tumor-specific immunological responses. Despite notable progress in tumor immunotherapy, nanovaccines still encounter considerable challenges such as low delivery efficiency, limited targeting ability, and suboptimal efficacy. With an aim of addressing these issues, engineering customized nanovaccines through modification or functionalization has emerged as a promising approach. These tailored nanovaccines not only enhance antigen presentation, but also effectively modulate immunosuppression within the tumor microenvironment. Specifically, they are distinguished by their diverse sizes, shapes, charges, structures, and unique physicochemical properties, along with targeting ligands. These features of nanovaccines facilitate lymph node accumulation and activation/regulation of immune cells. This overview of bespoke nanovaccines underscores their potential in both prophylactic and therapeutic applications, offering insights into their future development and role in cancer immunotherapy.
Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study
Authors: Christopher J Thang, David Garate, ​Sean O’Leary, George Golovko, Michael G Wilkerson, John S Barbieri
Journal: British Journal of Dermatology (2024)

We conducted a population-based retrospective cohort study on the TriNetX US Collaborative Network to investigate whether tetracycline-class antibiotic exposure is associated with idiopathic intracranial hypertension (IIH) development in people with acne. Doxycycline exposure conferred a significantly decreased risk of IIH compared with minocycline, and minocycline exposure was associated with a significantly increased risk of IIH compared with nonsystemic acne treatment. Our findings underscore the need to carefully consider the use of minocycline in acne treatment.
Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments
Authors: Ghazi O. Bou Ghanem, Lauren K. Wareham, David J. Calkins
Journal: Progress in Retinal and Eye Research (2024)

Glaucoma is the leading cause of irreversible blindness globally. The disease causes vision loss due to neurodegeneration of the retinal ganglion cell (RGC) projection to the brain through the optic nerve. Glaucoma is associated with sensitivity to intraocular pressure (IOP). Thus, mainstay treatments seek to manage IOP, though many patients continue to lose vision. To address neurodegeneration directly, numerous preclinical studies seek to develop protective or reparative therapies that act independently of IOP. These include growth factors, compounds targeting metabolism, anti-inflammatory and antioxidant agents, and neuromodulators. Despite success in experimental models, many of these approaches fail to translate into clinical benefits. Several factors contribute to this challenge. Firstly, the anatomic structure of the optic nerve head differs between rodents, nonhuman primates, and humans. Additionally, animal models do not replicate the complex glaucoma pathophysiology in humans. Therefore, to enhance the success of translating these findings, we propose two approaches. First, thorough evaluation of experimental targets in multiple animal models, including nonhuman primates, should precede clinical trials. Second, we advocate for combination therapy, which involves using multiple agents simultaneously, especially in the early and potentially reversible stages of the disease. These strategies aim to increase the chances of successful neuroprotective treatment for glaucoma.
Positive 18F-FDG and Negative 68Ga-FAPI-04 Findings in a Patient With Gallbladder Adenocarcinoma
Authors: Na Qi, Xing Chen, Zirong Zhou, Zengbei Yuan, Jun Zhao
Journal: Clinical Nuclear Medicine (2024)

Abstract Radiolabeled fibroblast activation protein inhibitor (FAPI) is considered as a potential alternative agent to 18 F-FDG for tumor-specific imaging. We report 18 F-FDG and 68 Ga-FAPI-04 PET/MR findings in a 67-year-old woman with gallbladder adenocarcinoma. The lesions showed intense 18 F-FDG uptake but limited 68 Ga-FAPI-04 uptake in PET/MR. This case emphasizes the necessity for nuclear clinicians to exercise caution when assessing gallbladder lesions with limited 68 Ga-FAPI-04 uptake, underscoring the continued relevance of 18 F-FDG in this diagnostic domain.
Transitional Neonatal Hypoglycemia and Adverse Neurodevelopment in Midchildhood
Authors: Marcia Roeper, Henrike Hoermann, Lisa M. Körner, Marvin Sobottka, Ertan Mayatepek, Sebastian Kummer, Thomas Meissner
Journal: JAMA Network Open (2024)

Importance The circumstances under which neonatal hypoglycemia leads to brain damage remain unclear due to a lack of long-term data on the neurodevelopment of affected children. As a result, diagnostic strategies and treatment recommendations are inconsistent. Objective To evaluate whether the occurrence of severe transitional neonatal hypoglycemia (defined as having at least 1 blood glucose measurement of 30 mg/dL or below) is associated with adverse neurodevelopment in midchildhood. Design, Setting, and Participants This cohort study using neurodevelopmental testing of a retrospectively recruited cohort was conducted at a single-center tertiary hospital in Germany between March 2022 and February 2023. Children with neonatal blood glucose screening data were randomly selected from all births between 2010 and 2015. Frequency matching for sex, birth weight, gestational age, socioeconomic status, and primary risk factors for neonatal hypoglycemia was performed. Children with persistent hypoglycemia diseases or any risk factor for adverse neurodevelopment except hypoglycemia were excluded. Data were analyzed between February 2023 and March 2023. Exposure At least 1 neonatal hypoglycemia measurement with blood glucose measuring 30 mg/dL or below vs all measured blood glucose levels above 30 mg/dL during postnatal blood glucose screening starting on the first day of life. Main Outcomes and Measures Cognitive function measured by full-scale IQ test. Secondary outcomes included standardized scales of motor, visual, and executive functions, and child behavior, each measured at ages 7 to 11 years. Results A total of 140 children (mean [SD] age 9.1 [1.3] years; 77 male [55.0%]) participated in the study. Children with severe neonatal hypoglycemia had a 4.8 points lower mean full-scale IQ than controls (107.0 [95% CI, 104.0-109.9] vs 111.8 [95% CI, 108.8-114.8]). They showed a 4.9-fold (95% CI, 1.5-15.5) increased odds of abnormal fine motor function and a 5.3-fold (95% CI, 2.1-13.3) increased odds of abnormal visual-motor integration. Significantly higher T scores for attention problems (58.2 [95% CI, 56.1-60.2] vs 54.6 [95% CI, 52.6-56.6]) and attention-deficit/hyperactivity disorder symptoms (58.2 [95% CI, 56.2-60.2] vs 54.7 [95% CI, 52.8-56.7]) were reported by parents. Conclusions and Relevance Neonatal hypoglycemia with blood glucose levels of 30 mg/dL or below was associated with an increased risk for suboptimal neurodevelopmental outcomes in midchildhood. These findings imply that treatment strategies should aim to prevent episodes of hypoglycemia at these severely low levels.
A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas
Authors: Pankaj B. Desai, Aniruddha S. Karve, Misam Zawit, Priyanka Arora, Nimita Dave, Joy Awosika, Ningjing Li, Bethany Fuhrman, Mario Medvedovic, Larry Sallans, Ady Kendler, Biplab DasGupta, David Plas, Richard Curry, Mario Zuccarello, Rekha Chaudhary, Soma Sengupta, Trisha M. Wise-Draper
Journal: Clinical Cancer Research (2024)

High-grade gliomas (HGG) carry a poor prognosis, with glioblastoma accounting for almost 50% of primary brain malignancies in the elderly. Unfortunately, despite the use of multiple treatment modalities, the prognosis remains poor in this population. Our preclinical studies suggest that the presence of aromatase expression, encoded by CYP19A1, is significantly upregulated in HGGs. Remarkably, we find that letrozole (LTZ), an FDA-approved aromatase inhibitor, has marked activity against HGGs.
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Authors: Viswanath Das, John H. Miller, Charanraj Goud Alladi, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch
Journal: Medicinal Research Reviews (2024)

Abstract As the world population ages, there will be an increasing need for effective therapies for aging‐associated neurodegenerative disorders, which remain untreatable. Dementia due to Alzheimer's disease (AD) is one of the leading neurological diseases in the aging population. Current therapeutic approaches to treat this disorder are solely symptomatic, making the need for new molecular entities acting on the causes of the disease extremely urgent. One of the potential solutions is to use compounds that are already in the market. The structures have known pharmacokinetics, pharmacodynamics, toxicity profiles, and patient data available in several countries. Several drugs have been used successfully to treat diseases different from their original purposes, such as autoimmunity and peripheral inflammation. Herein, we divulge the repurposing of drugs in the area of neurodegenerative diseases, focusing on the therapeutic potential of antineoplastics to treat dementia due to AD and dementia. We briefly touch upon the shared pathological mechanism between AD and cancer and drug repurposing strategies, with a focus on artificial intelligence. Next, we bring out the current status of research on the development of drugs, provide supporting evidence from retrospective, clinical, and preclinical studies on antineoplastic use, and bring in new areas, such as repurposing drugs for the prion‐like spreading of pathologies in treating AD.
The clinician-AI interface: intended use and explainability in FDA-cleared AI devices for medical image interpretation
Authors: Stephanie L. McNamara, Paul H. Yi, William Lotter
Journal: npj Digital Medicine (2024)

Abstract As applications of AI in medicine continue to expand, there is an increasing focus on integration into clinical practice. An underappreciated aspect of this clinical translation is where the AI fits into the clinical workflow, and in turn, the outputs generated by the AI to facilitate clinician interaction in this workflow. For instance, in the canonical use case of AI for medical image interpretation, the AI could prioritize cases before clinician review or even autonomously interpret the images without clinician review. A related aspect is explainability – does the AI generate outputs to help explain its predictions to clinicians? While many clinical AI workflows and explainability techniques have been proposed, a summative assessment of the current scope in clinical practice is lacking. Here, we evaluate the current state of FDA-cleared AI devices for medical image interpretation assistance in terms of intended clinical use, outputs generated, and types of explainability offered. We create a curated database focused on these aspects of the clinician-AI interface, where we find a high frequency of “triage” devices, notable variability in output characteristics across products, and often limited explainability of AI predictions. Altogether, we aim to increase transparency of the current landscape of the clinician-AI interface and highlight the need to rigorously assess which strategies ultimately lead to the best clinical outcomes.
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Authors: Hossein-Ardeschir Ghofrani, Gérald Simonneau, Andrea M D'Armini, Peter Fedullo, Luke S Howard, Xavier Jaïs, David P Jenkins, Zhi-Cheng Jing, Michael M Madani, Nicolas Martin, Eckhard Mayer, Kelly Papadakis, Dominik Richard, Nick H Kim, Irene Lang, Christian Kähler, Marion Delcroix, Zoheir Bshouty, Pablo Sepulveda Varela, Zhi-Cheng Jing, Yuanhua Yang, Jinming Liu, Gangcheng Zhang, Nuofu Zhang, Yuhong Mi, Xianyang Zhu, Pavel Jansa, Xavier Jaïs, Grégoire Prévot, Hélène Bouvaist, Olivier Sanchez, Friedrich Grimminger, Matthias Held, Heinrike Wilkens, Stephan Rosenkranz, Ekkehard Grünig, Kristóf Karlócai, András Temesvári, Istvan Edes, Sigita Aidietienė, Skaidrius Miliauskas, Tomas Rene Pulido Zamudio, Carlos Jerjes Sanchez, Anton Vonk Noordegraaf, Jerzy Lewczuk, Piotr Podolec, Jarosław Kasprzak, Tatiana Mularek-Kubzdela, Ryszard Grzywna, Keertan Dheda, Olga Moiseeva, Alexander Chernyavskiy, Vladimir Shipulin, Olga Barbarash, Tamila Martynyuk, Hyung-Kwan Kim, Jun-Bean Park, Jae Seung Lee, Rudolf Speich, Silvia Ulrich, John-David Aubert, Arintaya Phrommintikul, Nattapong Jaimchariyatam, Suree Sompradeekul, Zeynep Pinar Onen, Gulfer Okumus, Lyubomyr Solovey, Volodymyr Gavrysyuk, Luke Howard, Joanna Pepke-Zaba, Robin Condliffe, John McConnell, Kim Kerr, Lan Hieu Nguyen, Nguyen Vinh Pham
Journal: The Lancet Respiratory Medicine (2024)
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Authors: Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Courtney DiNardo, Ghayas Issa, Guillermo Montalban-Bravo, Nicholas Short, Koji Sasaki, Debra Bull-Linderman, Naval Daver, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia
Journal: The Lancet Haematology (2024)